Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.54 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)2.59M
Market Cap
$529.90M
Enterprise Value$227.65M
Total Cash (Recent Filing)$164.32M
Total Debt (Recent Filing)$75.32M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Oct 30, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding61,545,270
10 Day Avg. Volume1,963,944
30 Day Avg. Volume2,586,556
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue-29.04
Enterprise Value/Gross Profit-26.97
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$15.00Price Target Upside68.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyVerastem's VS-7375 has shown promising efficacy in NSCLC patients with a notable 68.8% overall response rate and 93.8% disease control rate, indicating strong clinical activity.
Financial PerformanceVerastem reported revenues of $2.1M for the quarter, higher than consensus estimate of $1.0M, and a net loss of $0.35 per diluted share, compared to consensus estimated net loss of $0.73 per share.
Market ExpansionThe company's KRASG12D inhibitor program presents a significant market opportunity, estimated at over $1.5 billion.
Bears Say
Commercialization ChallengesDespite broad payer support and reimbursement, no major headwinds are expected to impact commercialization of Avmapki Fakzynja, but challenges remain in ramping up sales.
Financial LossVerastem reported a net loss of $0.35 per diluted share, despite higher than expected revenues.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.54 and its highest was $11.24 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $529.90M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Oct 30, 2025 which is in 33 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Aug 07, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.728 by $0.338.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.62.
How many shares outstanding does Verastem have?
Verastem has 61,545,270 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.728. Following the earnings report the stock price went up 19.929%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
Verastem Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (68.73% Upside)
$15.00 (68.73% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 62.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
227.37%
12-Months-Change
Fundamentals
Return on Equity
-437.92%
Trailing 12-Months
Asset Growth
85.60%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc. (VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life for cancer patients. The company primarily operates in the oncology sector, with a strong emphasis on targeting malignant cells and the tumor microenvironment. Its core products and services revolve around innovative therapies for cancer treatment, particularly targeting specific pathways involved in cancer cell proliferation and survival.
VSTM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment, with significant achievements such as the early FDA approval and successful commercial launch of AVMAPKI FAKZYNJA CO-PACK. These positive developments were partially offset by increased R&D expenses and net loss. However, the highlights significantly outweigh the lowlights, indicating strong momentum and future potential.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$15.00
▲(68.73% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.40% Insiders
7.09% Mutual Funds
48.85% Other Institutional Investors
31.90% Public Companies and
Individual Investors